BBNX vs BVS: stock comparison and AI forecast
Beta Bionics, Inc. (BBNX) and Bioventus Inc. (BVS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BBNX Beta Bionics, Inc.
- Market Cap
- $821M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
BVS Bioventus Inc.
- Price
- $10.95 +2.5% · 6M
- Market Cap
- $747M
- P/E Ratio
- 30.4x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BBNX and BVS have similar market capitalizations ($821M and $747M).
- BVS carries 1.59 times debt per unit of equity, against 0.11 times for BBNX.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BBNX | BVS |
|---|---|---|
| Market Cap | $821M | $747M |
| P/E Ratio | – | 30.40x |
| P/B Ratio | 2.05x | 3.11x |
| EPS | $-2.14 | $0.36 |
| Book Value/Share | $7.38 | $3.52 |
| Revenue/Share | $2.34 | $8.58 |
| FCF/Share | $-1.21 | $1.24 |
Profitability & Margins
| Metric | BBNX | BVS |
|---|---|---|
| ROE | -20.7% | – |
| ROA | -18.7% | – |
| ROIC | -22.5% | 11.0% |
| Gross Margin | 58.6% | 68.7% |
| Operating Margin | -72.8% | 9.7% |
| Net Margin | -65.3% | – |
| EBT Margin | -72.8% | 6.8% |
| Tax Rate | – | -60.3% |
Financial Health
| Metric | BBNX | BVS |
|---|---|---|
| Current Ratio | 8.92x | 1.68x |
| Quick Ratio | 8.22x | 1.16x |
| D/E Ratio | 0.11x | 1.59x |
| Financial Leverage | 1.11x | 2.80x |
| Working Capital | $260M | $108M |
Cash Flow
| Metric | BBNX | BVS |
|---|---|---|
| Operating Cash Flow | -$59M | $87M |
| Free Cash Flow | -$66M | $85M |
| Capital Spending | -$7M | -$2M |
| OCF Growth YoY | – | 56.1% |
| FCF Growth YoY | – | 58.9% |
| FCF/Sales | -51.8% | 14.5% |
| CapEx/Sales | 5.2% | 0.4% |
Operational Efficiency
| Metric | BBNX | BVS |
|---|---|---|
| Asset Turnover | 0.29x | 0.87x |
| Receivables Turnover | 6.2x | 4.2x |
| Inventory Turnover | 2.3x | 2.2x |
| Fixed Assets Turnover | 10.8x | 60.3x |
| Days Sales Outstanding | 59 days | 86 days |
| Days Inventory | 159 days | 165 days |
| Payables Period | 32 days | 51 days |
| Cash Conversion Cycle | 186 days | 200 days |
Income Statement
| Metric | BBNX | BVS |
|---|---|---|
| Total Revenue | $127M | $586M |
| Operating Income | -$93M | $57M |
| Net Income | -$83M | – |
| R&D Expense | $43M | $12M |
| SG&A Expense | $179M | $327M |
| Cost of Goods Sold | $53M | $183M |
Dividend & Shareholder Information
| Metric | BBNX | BVS |
|---|---|---|
| Shares Outstanding | 54M | 68M |
BBNX vs BVS: stock comparison and AI forecast
Which is bigger, BBNX or BVS?
BBNX and BVS have similar market capitalizations ($821M and $747M).
Which one does Intratio's AI model rank higher, BBNX or BVS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.